Compare PAVM & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAVM | GNPX |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 6.4M |
| IPO Year | 2016 | 2018 |
| Metric | PAVM | GNPX |
|---|---|---|
| Price | $10.56 | $2.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $510.00 | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 907.7K |
| Earning Date | 03-24-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $450.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.00 | $1.71 |
| 52 Week High | $28.44 | $55.00 |
| Indicator | PAVM | GNPX |
|---|---|---|
| Relative Strength Index (RSI) | 56.23 | 41.61 |
| Support Level | $10.24 | $1.99 |
| Resistance Level | $11.34 | $2.29 |
| Average True Range (ATR) | 1.34 | 0.28 |
| MACD | -0.22 | -0.04 |
| Stochastic Oscillator | 40.36 | 10.74 |
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.